1. Home
  2. VKTX vs NFE Comparison

VKTX vs NFE Comparison

Compare VKTX & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VKTX
  • NFE
  • Stock Information
  • Founded
  • VKTX 2012
  • NFE 2014
  • Country
  • VKTX United States
  • NFE United States
  • Employees
  • VKTX N/A
  • NFE N/A
  • Industry
  • VKTX Biotechnology: Pharmaceutical Preparations
  • NFE Oil/Gas Transmission
  • Sector
  • VKTX Health Care
  • NFE Utilities
  • Exchange
  • VKTX Nasdaq
  • NFE Nasdaq
  • Market Cap
  • VKTX 3.4B
  • NFE 3.2B
  • IPO Year
  • VKTX 2015
  • NFE 2019
  • Fundamental
  • Price
  • VKTX $34.07
  • NFE $11.17
  • Analyst Decision
  • VKTX Strong Buy
  • NFE Buy
  • Analyst Count
  • VKTX 14
  • NFE 5
  • Target Price
  • VKTX $97.29
  • NFE $17.40
  • AVG Volume (30 Days)
  • VKTX 4.8M
  • NFE 3.5M
  • Earning Date
  • VKTX 02-05-2025
  • NFE 03-03-2025
  • Dividend Yield
  • VKTX N/A
  • NFE 2.69%
  • EPS Growth
  • VKTX N/A
  • NFE N/A
  • EPS
  • VKTX N/A
  • NFE 0.91
  • Revenue
  • VKTX N/A
  • NFE $2,417,879,000.00
  • Revenue This Year
  • VKTX N/A
  • NFE N/A
  • Revenue Next Year
  • VKTX $986.87
  • NFE $27.71
  • P/E Ratio
  • VKTX N/A
  • NFE $12.34
  • Revenue Growth
  • VKTX N/A
  • NFE 11.48
  • 52 Week Low
  • VKTX $28.64
  • NFE $7.82
  • 52 Week High
  • VKTX $99.41
  • NFE $35.58
  • Technical
  • Relative Strength Index (RSI)
  • VKTX 51.41
  • NFE 32.82
  • Support Level
  • VKTX $28.90
  • NFE $11.44
  • Resistance Level
  • VKTX $34.37
  • NFE $12.79
  • Average True Range (ATR)
  • VKTX 2.37
  • NFE 0.75
  • MACD
  • VKTX 0.66
  • NFE -0.21
  • Stochastic Oscillator
  • VKTX 70.06
  • NFE 1.49

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

About NFE New Fortress Energy Inc.

New Fortress Energy is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to both lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include terminals and infrastructure, or T&I, and ships.

Share on Social Networks: